Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Royalty Pharma plc (NASDAQ:RPRX) announced on Sunday a funding agreement of up to $500 million to accelerate the clinical development of Teva’s anti-IL-15 antibody, TEV-‘408.IL-15 is a key cytokine involved in multiple immune-mediated disease pathways.Phase 1b data from the ongoing TEV-‘408 vitiligo study provide preliminary support for IL-15 as a potential therapeutic target to treat a wide variety of autoimmune conditions.Vitiligo is a chronic autoimmune ...